Administration Information Clause Samples

The 'Administration Information' clause outlines the key administrative details relevant to the agreement, such as contact information, addresses for notices, and the parties responsible for managing the contract. Typically, it specifies where official communications should be sent, who the designated representatives are, and may include instructions for updating this information if changes occur. This clause ensures that all parties have clear, up-to-date points of contact, reducing the risk of miscommunication and facilitating smooth contract administration.
Administration Information. Entrust may store information in and related to Customer’s Order and Management Account and information generated by Customer’s usage of the Hosted Service, such as Customer’s access credentials, contact information for Agents, and entitlement consumption (“Administration Information”) in the United States and/or Canada, and may process Administration Information for the purposes of billing, providing Support and to investigate fraud, abuse or violations of this Agreement in the United States, Canada and other locations where Entrust maintains its support and investigation personnel.
View SourceView Similar (7)
Administration Information. If measuring ciclosporin trough levels, ask the patient to omit morning dose of ciclosporin. • Levels not needed for dermatological doses but may be indicated to check for toxicity. There is no correlation between efficacy of treatment in psoriasis and serum levels of ciclosporin. • Indefinite as long as efficacy and safety profiles are maintained. • Licensed for 8 weeks’ use in atopic dermatitis in patients aged over 16 years. • Check FBC, eGFR, ALT and albumin, BP and glucose, every 2 weeks, until a stable dose has been achieved for 6 weeks. • Watch creatinine if a NSAID is added (particularly diclofenac). Once the patient has been on a stable dose for 6 weeks: • check FBC, eGFR, ALT and albumin, BP and glucose every month for 3 months. Where there is a low risk of toxicity, onward monitoring may then be reduced to 3-monthly as a minimum, after discussion with the relevant consultant, and usually not in children or those at high risk of toxicity, with renal impairment. Risk factors for toxicity include: a history of adverse drug events; medical co-morbidities including renal and liver impairment (e.g. NAFLD) and malignancy; patients at the extremes of weight (BMI <18 or >30 kg/m2); old age (>80 years). Patients on concomitant DMARDs, especially leflunomide, should have monthly monitoring. Be aware that creatinine may increase if NSAID is added (particularly diclofenac). • Check blood pressure as above and act on abnormal readings If BP cannot be controlled, stop ciclosporin. • Rheumatology / Dermatology medical team are responsible for the initiation and six weeks’ prescription of ciclosporin at a stable dose. • Patient education will be undertaken within the Rheumatology/Dermatology multidisciplinary team. Pregnancy testing / contraceptive cover to be checked. • Advice regarding care in the sun. • Check FBC, eGFR, ALT and albumin, BP and glucose, every 2 weeks, until a stable dose has been achieved for 6 weeks. • Patient to ensure disease is controlled and drug efficacy. • Watch creatinine if a NSAID is added (particularly diclofenac). From six weeks after the stable dose has been commenced, to prescribe and monitor ciclosporin therapy, and to communicate adverse events to the appropriate Rheumatology/Dermatology Consultant.
View Source
Administration Information. Long-term If patients need pre-treatment with nebulised salbutamol 2.5mg, this can be mixed directly with colistin (immediately prior to use) and nebulised. Reference: ▇▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇ NR, ▇▇▇▇▇▇▇▇ ▇▇ (1992) Cystic Fibrosis Inhalation Therapy: Stability of a Combined Salbutamol/Colistin Solution. Australian Journal of Hospital Pharmacy. 22(5):378-80 Initial specialist monitoring: • Spirometry pre and post the initial (test) dose. Ongoing specialist monitoring: • Sputum microbiology • On-going compliance and tolerance • Administration of the first (test) dose with lung function monitoring • Training the patient/carer in use of nebulised antibiotics • Prescription and supply (via hospital pharmacy) of the first month of colistin and diluents • Supply and ongoing maintenance of an appropriate nebuliser/compressor system • On-going supply of plastic syringes to measure diluent volumes • Assess response to treatment and to discontinue if no benefit • Ongoing clinical and microbiological review • On-going prescription of colistin and diluents (in plastic ampoules) • Diluents Diluents must be supplied in 5ml plastic ampoules for ease of use and to avoid the risks associated with breaking glass ampoules. Where part ampoules need to be used, volumes do not need to be measured accurately using a syringe, they can be estimated from the original volume in the vial. Recommended method of reconstitution: The method used for the test dose should be continued. Any change in the diluents used will require the test dose to be repeated. o Method 1: 5ml sodium chloride 0.9% o Method 2: 2ml water + 2ml sodium chloride 0.9% (least likely to cause bronchoconstriction) • Nebuliser and associated equipment (Pari LC or eFlow) This will be supplied by the hospital, and will be serviced / replaced when required. • Expiratory filters These are used while patients are in hospital to minimise risks of antibiotic resistance and staff sensitisation due to repeated exposure. At home the use of expiratory filters is not considered to be necessary provided the patient nebulises alone in a well ventilated room. If a particular patient wants to use filters they may be purchased direct from PARI Medical Limited. It is recommended that pets are not present in the room when nebulisation occurs. • Suspected side-effects / adverse reactions • Deterioration in clinical status • British Thoracic Society guideline for non-CF bronchiectasis. ▇ ▇ ▇▇▇▇▇▇▇, ▇ ▇▇▇▇▇▇, A T ▇▇▇▇. Thorax July 2010 • Britis...
View Source
Administration Information 
View SourceView Similar (11)

Related to Administration Information

  • Union Information On a quarterly basis, the Employer shall provide the Union with the name, address, telephone number, hire date, classification, employment status, and pay rate of bargaining unit members.

  • Transaction Information The Adviser shall furnish to the Trust such information concerning portfolio transactions as may be necessary to enable the Trust or its designated agent to perform such compliance testing on the Funds and the Adviser’s services as the Trust may, in its sole discretion, determine to be appropriate. The provision of such information by the Adviser to the Trust or its designated agent in no way relieves the Adviser of its own responsibilities under this Agreement.

  • Verizon Information Upon request by CBB, Verizon shall make available to CBB the following information to the extent that Verizon provides such information to its own business offices: a directory list of relevant NXX codes, directory and Customer Guide close dates, and Yellow Pages headings. Verizon shall also make available to CBB, on Verizon’s Wholesale website (or, at Verizon’s option, in writing) Verizon’s directory listings standards and specifications.

  • Administrative information Time limit for receipt of tenders or requests to participate

  • Confidential Information Protections 4.1 At all times during and after the Employee’s employment, the Employee will hold in confidence and will not disclose, use, lecture upon, or publish any of Company’s Confidential Information (defined below), except as may be required in connection with the Employee’s work for Company, or as expressly authorized by the Board. The Employee will obtain the written approval of the Board before publishing or submitting for publication any material (written, oral, or otherwise) that relates to the Employee’s work at Company and/or incorporates any Confidential Information. The Employee hereby assigns to Company any rights the Employee may have or acquire in any and all Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Company and its assigns.